Peter Lougheed Centre Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients

    NEXT STORY
    Innovation Pharma Provides Study Details for Ongoing Phase 2 Clinical Trial of Brilacidin in Hospitalized COVID-19 Patients
    PREV STORY
    Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Press Release Oncology Venture A/S Issues 1,619,912 Shares in Exchange for Previously Annulled Warrants

    author_avatar
    NASDAQ Market News

    CORRECTION: BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures

    author_avatar
    NASDAQ Market News

    Oasmia publishes its annual report and adjusts accounts due to write-downs – auditors do not recommend former board to be granted discharge from liability

    author_avatar
    NASDAQ Market News